USFDA gives tentative approval to Alembic for generic Pradaxa capsules

It may not be indicated for certain other uses due to unexpired exclusivities for the RLD for such uses.

200
USFDA Approval
USFDA Approval

Last Updated on October 15, 2024 by The Health Master

Alembic Pharmaceuticals Limited has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for dabigatran etexilate capsules, 75 mg, 110 mg, and 150 mg.

The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Pradaxa capsules, 75 mg, 110 mg, and 150 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer).

Dabigatran etexilate capsules, are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients, treatment of deep venous thrombosis and pulmonary embolism in adult patients, reduction in the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients, prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients following hip replacement surgery.

It may not be indicated for certain other uses due to unexpired exclusivities for the RLD for such uses.

Dabigatran etexilate capsules, 75 mg, 110 mg, and 150 mg have an estimated market size of US$ 465 million for twelve months ending December 2021 according to IQVIA.

Alembic has received a cumulative total of 162 ANDA approvals (139 final approvals and 23 tentative approvals) from US FDA.

USFDA approves Cell Therapy for earlier lymphoma

USFDA approves Ozempic 2 mg to treat Type-II Diabetes

USFDA gives nod to Lupin for Sildenafil for oral suspension

USFDA gives approval to Glenmark Pharma for Lacosamide Tablets

USFDA approves drug for treatment of Seizures associated with rare disease

USFDA approves new Bristol Myers cancer Immunotherapy

USFDA issues 4 Observations to Lupin for Tarapur Facility

Dr Reddy’s launches generic Methylprednisolone Sodium Succinate for injection

Certain Products recalled due to Microbial Contamination

USFDA approves Cell Therapy for earlier lymphoma

Drug Recall: IDArubicin Hydrochloride Injection recalled due to this reason

USFDA gives 13 observations to Lupin

Govt further extends timeline to apply for slots under PLI scheme

CDSCO panel gives nod to Roche for Anticancer Drug Entrectinib Capsules

Latest Notifications regarding Pharmaceuticals

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news